Project Grant R01HL176542
Award Date
2/1/25
Completion Date
12/31/29
Dollars Obligated
$730K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award of $629,319 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Emory University supports research to overcome defects in the CFTR gene that cause cystic fibrosis. The research aims to investigate how modulating ribosomal proteins can rescue the synthesis and assembly of CFTR variants with premature termination codons, which are associated with more severe disease. The project will explore the mechanisms by which ribosomal...
This $437,156 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a 5-year study to investigate the mechanisms by which cystic fibrosis (CF) impacts pancreatic islet cell function and insulin release, leading to the development of CF-related diabetes (CFRD). The research will be conducted by The Governors of the University of...
This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program will provide $750,672 to Stanford University to conduct pharmacogenomic research to identify protein quality control (PQC) mechanisms that govern the stability and trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The goal is to develop novel therapies for cystic fibrosis patients who do not respond to existing CFTR...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,389,542 to the University of Pittsburgh to conduct research on how CFTR corrector compounds used to treat cystic fibrosis (CF) affect calcium-activated potassium (KCa) channels. The primary goals are to: 1) Define the mechanisms by which CFTR correctors inhibit the KCa3.1 and KCa2.x channels and the effects on human bronchial epithelial cell function; 2) Define...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, in the amount of $1,788,091.00 with a start date of August 1, 2024 and end date of April 30, 2028. The purpose of this grant is to investigate the mechanisms underlying impaired resolution of inflammation in the lungs of patients with cystic fibrosis (CF) and to...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $574,000 to The University of Texas Southwestern Medical Center to investigate the effects of estrogen on neutrophil function and airway inflammation in cystic fibrosis (CF) and non-CF bronchiectasis. The research aims to understand how estrogen impacts neutrophil dysregulation and inflammation, which may contribute to sex differences in lung disease and outcomes in...
This $783,000 Project Grant award from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a non-viral base editing platform for treating cystic fibrosis (CF) caused by nonsense mutations. The key objectives are: 1) chemical refinement of adenine base editors (ABEs) to optimize on-target gene editing, 2) development and fine-tuning of lipid nanoparticle (LNP) formulations for pulmonary delivery, and 3) in vivo validation using a CF...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $391,250.00 to Emory University from March 1, 2025 to February 29, 2028. The project aims to investigate fibrinogen as a mediator of COVID-19-associated coagulopathy, a major driver of severe COVID-19 illness. Specifically, the research will define the impact of therapeutic plasma exchange on blood rheology and vascular integrity, as well...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The study aims to define how MitoNEET regulates pulmonary artery smooth muscle cell mitochondrial function and proliferation, examine MitoNEET's function during PH pathogenesis in a rat model, and test MitoNEET and bioenergetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $683,564 to The Trustees of the University of Pennsylvania to conduct research on alveolar epithelial stress signaling in lung fibrosis. The key objectives are to determine how aberrant transitional epithelial cells contribute to fibrosis, and to define how the PERK-ISR signaling pathway impacts epithelial differentiation and promotes fibrosis. The research will...